Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

Anti-Human CD49D (Integrin alpha 4) (Natalizumab)

Product Sizes
50 µg
£540.00
12-8042-50UG
100 µg
£760.00
12-8042-100UG
About this Product
SKU:
12-8042
Additional Names:
CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV
translate.label.attr.clone:
Hu114
Clonality:
Monoclonal
Extra Details:
Expression Host : HEK-293 Pathogen Testing : To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens; all of this recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Natalizumab. Natalizumab binds to the alpha 4 subunit of alpha4beta1 and alpha4beta7 integrins. This product is for research use only. Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)); and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and alpha4beta1-integrin interaction is necessary for leukocyte adhesion; firm attachment; and transmigration across the blood-brain barrier into the CNS. Natalizumab; a recombinant; humanized antibody; binds to alpha4beta1 -integrin and blocks its interaction with VCAM-1. Hence; leukocyte migration into brain tissue is inhibited; thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking alpha4beta7-integrin with a humanized; monoclonal antibody; specific to the alpha4beta7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue; thus; reducing inflammation in the gut.2 This cost-effective; research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects.
Host:
Human
Immunogen:
RAMOS cell line injected into mice.
Isotype:
Human IgG1k
Purification:
>=95% monomer by analytical SEC
Reactivities:
Human
Shipping Conditions:
Blue Ice
Storage Conditions:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at -80[o]C. Avoid Repeated Freeze Thaw Cycles.
Supplier:
Abeomics
Type:
Antibodies:Monoclonal Antibody